Cancer Letters
Volume 194, Issue 2 , Pages 221-233, 15 May 2003

Telomerase as tumor marker

  • Eiso Hiyama

      Affiliations

    • Department of General Medicine, Hiroshima University, Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Hiroshima, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-82-257-5216; fax: +81-82-257-5219
  • ,
  • Keiko Hiyama

      Affiliations

    • Department of Translational Cancer Research, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Hiroshima, Japan

Received 4 September 2002; received in revised form 30 October 2002; accepted 30 October 2002.

Abstract 

Telomerase, a critical enzyme responsible for continuous cell growth, is repressed in most somatic cells except proliferating progenitor cells and activated lymphocytes, and activated in approximately 85% of human cancer tissues. Telomerase activity is a useful cancer-cell detecting marker in some types of cancers in which almost all cases show telomerase activation. In other types in which telomerase becomes upregulated according to tumor progression, it is a useful prognostic indicator. Detection of human telomerase reverse transcriptase (hTERT) mRNA or protein in various clinical samples is also applicable. However, careful attention should be paid to the false negative results due to the instability of this enzyme or hTERT mRNA and the existence of polymerase chain reaction inhibitors as well as the false-positive results due to the contamination by normal cells with telomerase activity. If these pitfalls are avoided, in situ detection of hTERT mRNA or protein will facilitate the reliability of telomerase as a tumor marker.

Telomerase, Human telomerase reverse transcriptase, Human telomerase RNA component, Biopsy, Fine needle aspiration, Cytology, Telomeric repeat amplification protocol, Diagnosis, Prognosis, Immunohistochemistry, Tumor, Cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(02)00709-7

doi:10.1016/S0304-3835(02)00709-7

Cancer Letters
Volume 194, Issue 2 , Pages 221-233, 15 May 2003